📊 STAA Key Takeaways
Is Staar Surgical Co (STAA) a Good Investment?
STAA faces significant operational deterioration with 23.7% revenue decline and widening losses (-$80.4M net loss), coupled with negative operating cash flow of -$34.2M indicating the business is not self-sustaining. While the fortress balance sheet ($153.2M cash, zero debt) provides runway, current cash burn rates suggest limited time for operational recovery before depletion risk emerges.
Why Buy Staar Surgical Co Stock? STAA Key Strengths
- Exceptional 76.2% gross margin demonstrates strong pricing power and product differentiation in ophthalmic market
- Fortress balance sheet with $153.2M cash, zero debt, and 4.55x current ratio provides significant financial flexibility and runway
- Debt-free capital structure eliminates refinancing risk and interest burden, maximizing available resources for recovery initiatives
STAA Stock Risks: Staar Surgical Co Investment Risks
- Sharp 23.7% revenue decline signals lost market share, weakened demand, or structural market disruption requiring urgent strategic response
- Significant operating losses (-$91.7M) and negative operating cash flow (-$34.2M) indicate the business is not generating cash from core operations
- At current burn rate (~$40M annually in FCF), cash runway is limited to 3-4 years without return to profitability or positive cash generation
Key Metrics to Watch
- Revenue trend stabilization and return to growth - critical inflection point for business viability
- Operating cash flow return to positive - essential for sustainability beyond balance sheet cushion
- Gross margin stability - deterioration would compound profitability challenges and suggest pricing pressure or cost structure issues
Staar Surgical Co (STAA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.55x current ratio provides a solid financial cushion.
STAA Profit Margin, ROE & Profitability Analysis
STAA vs Market Sector: How Staar Surgical Co Compares
How Staar Surgical Co compares to Market sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Staar Surgical Co Stock Overvalued? STAA Valuation Analysis 2026
Based on fundamental analysis, Staar Surgical Co has mixed fundamental signals relative to the Market sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Staar Surgical Co Balance Sheet: STAA Debt, Cash & Liquidity
STAA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Staar Surgical Co's revenue has grown significantly by 40% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.43 reflects profitable operations.
STAA Revenue Growth, EPS Growth & YoY Performance
STAA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $88.6M | $8.9M | $0.18 |
| Q2 2025 | $44.3M | $4.0M | $0.08 |
| Q1 2025 | $42.6M | -$3.3M | $-0.07 |
| Q3 2024 | $80.3M | $4.8M | $0.10 |
| Q2 2024 | $92.3M | $4.0M | $0.08 |
| Q1 2024 | $73.5M | $2.7M | $0.05 |
| Q3 2023 | $76.0M | $4.8M | $0.10 |
| Q1 2023 | $63.2M | $2.7M | $0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Staar Surgical Co Dividends, Buybacks & Capital Allocation
STAA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Staar Surgical Co (CIK: 0000718937)
📋 Recent SEC Filings
❓ Frequently Asked Questions about STAA
What is the AI rating for STAA?
Staar Surgical Co (STAA) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are STAA's key strengths?
Claude: Exceptional 76.2% gross margin demonstrates strong pricing power and product differentiation in ophthalmic market. Fortress balance sheet with $153.2M cash, zero debt, and 4.55x current ratio provides significant financial flexibility and runway.
What are the risks of investing in STAA?
Claude: Sharp 23.7% revenue decline signals lost market share, weakened demand, or structural market disruption requiring urgent strategic response. Significant operating losses (-$91.7M) and negative operating cash flow (-$34.2M) indicate the business is not generating cash from core operations.
What is STAA's revenue and growth?
Staar Surgical Co reported revenue of $239.4M.
Does STAA pay dividends?
Staar Surgical Co does not currently pay dividends.
Where can I find STAA SEC filings?
Official SEC filings for Staar Surgical Co (CIK: 0000718937) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is STAA's EPS?
Staar Surgical Co has a diluted EPS of $-1.62.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is STAA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Staar Surgical Co has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is STAA stock overvalued or undervalued?
Valuation metrics for STAA: ROE of -23.4% (sector avg: 15%), net margin of -33.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy STAA stock in 2026?
Our dual AI analysis gives Staar Surgical Co a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is STAA's free cash flow?
Staar Surgical Co's operating cash flow is $-34.2M, with capital expenditures of $5.8M. FCF margin is -16.7%.
How does STAA compare to other Market stocks?
Vs Default sector averages: Net margin -33.6% (avg: 12%), ROE -23.4% (avg: 15%), current ratio 4.55 (avg: 1.8).